This proportion is slightly higher than that observed in the TCGA cohort (21.7%), although both values are consistent with previous reports of a 20–30% prevalence in IDH-mutant astrocytomas [3] and with the high frequency of this mutation in brain tissue (Figure 3b). The gene discussed is IDH2; the disease is astrocytoma (excluding glioblastoma).